GT
ICPT

Glenmede Trust’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Glenmede Trust’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-23
Closed – – 2389
2020
Q3 		$0 Hold
23
– – ﹤0.01% 2615
2020
Q2 		$1K Buy
+23
New +$1.78K ﹤0.01% 2399
2017
Q4 		– Sell
-11
Closed – – 2831
2017
Q3 		$0 Buy
+11
New +$1.19K ﹤0.01% 2869
2017
Q1 		– Sell
-125
Closed -$13K – 2769
2016
Q4 		$13K Sell
125
-157
-56% -$18.7K ﹤0.01% 2042
2016
Q3 		$46K Buy
282
+187
+197% +$29.5K ﹤0.01% 1642
2016
Q2 		$13K Buy
+95
New +$13.9K ﹤0.01% 2040
2014
Q2 		– Sell
-110
Closed -$36K – 2405
2014
Q1 		$36K Buy
+110
New +$37.1K ﹤0.01% 1747

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Glenmede Trust's ICPT Position: Q4 2020 in Review

Glenmede Trust sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2020, closing a stake of 23 shares.

Glenmede Trust first reported a position in ICPT in Q1 2014 and held it in 7 quarters. The position peaked at $46K in Q3 2016. 175 funds tracked by Wall St. Rank hold ICPT as of Q4 2020.

  • Glenmede Trust reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 23 Intercept Pharmaceuticals, Inc. shares in Q4 2020.
  • Glenmede Trust first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 7 quarters.
  • Glenmede Trust's Intercept Pharmaceuticals, Inc. position peaked at $46K in Q3 2016.
  • 175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.